Physicians' Academy for Cardiovascular Education

Icosapent Ethyl Resources

Tackling risk reduction in ASCVD: A clinical case

10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD

Addressing late-breaking data on triglycerides, fibrates and omega-3FAs

15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MD

11 Practical implications of REDUCE-IT

10' education - Oct. 28, 2022 - Prof. Subodh Verma, MD, PhD

A continuum of multifactorial benefits of icosapent ethyl?

10' education - Oct. 11, 2022 - Prof. Magnus Bäck, MD, PhD

Recent clinical insights into icosapent ethyl

10' education - Oct. 3, 2022 - Prof. Deepak Bhatt, MD

Finding a place for fish oil in CVD prevention

10' education - Sep. 7, 2022 - Prof. Chris Packard, PhD

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

A call to solve the controversy on omega-3FAs trials

5' education - May 17, 2021 - Prof. Eileen Handberg, PhD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides

10' education - Sep. 23, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Less coronary plaque progression with EPA but not EPA/DHA in statin-treated patients

Literature - Jan. 5, 2023 - Sheppard JP et al. - JACC Cardiovasc Imaging. 2022

In a systematic review and meta-analysis, statin plus EPA therapy led to greater percent and absolute reductions in total and lipid plaque volumes compared with statin only, while statin plus EPA/DHA therapy had no effect.

Tackling risk reduction in ASCVD: A clinical case

10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD
Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl.

Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl.

Addressing late-breaking data on triglycerides, fibrates and omega-3FAs

15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MD
At the end of AHA 2022, an international expert panel discusses the latest results of trials with pemafibrate and EPA. What do these findings mean for management of patients in clinical practice?

At the end of AHA 2022, an international expert panel discusses the latest results of trials with pemafibrate and EPA. What do these findings mean for management of patients in clinical practice?

Icosapent ethyl has minimal effect on 7 atherosclerotic biomarkers

Literature - Nov. 14, 2022 - Ridker PM, et al. - Circulation. 2022

In a REDUCE-IT substudy, icosapent ethyl had little to no effect on biomarkers associated with atherosclerotic disease, such as IL-1β, IL-6, oxidized LDL-c, and Lp(a). However, mineral oil increased these levels.

Effects of purified EPA on CV events in patients with CAD on statin therapy

News - Nov. 7, 2022

AHA 2022 The RESPECT-EPA study evaluated the effects of highly purified EPA in combination with statin therapy on CV events in Japanese patients with chronic CAD.

Similar benefit of icosapent ethyl in subgroups of patients based on smoking status

Literature - Oct. 31, 2022 - Miller M, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

REDUCE-IT showed that icosapent ethyl (IPE) lowers the risk of ischemic events by 25% in high-risk patients with hypertriglyceridemia already receiving statin therapy. But can IPE also reduce the risk of ischemic events attributable to smoking in these patients?

11 Practical implications of REDUCE-IT

10' education - Oct. 28, 2022 - Prof. Subodh Verma, MD, PhD
In this presentation, Prof. Subodh Verma presents 11 clinical implications of the REDUCE-IT trial with icosapent ethyl.

In this presentation, Prof. Subodh Verma presents 11 clinical implications of the REDUCE-IT trial with icosapent ethyl.

A continuum of multifactorial benefits of icosapent ethyl?

10' education - Oct. 11, 2022 - Prof. Magnus Bäck, MD, PhD
What are potential mechanisms that may explain the benefits observed with icosapent ethyl? Prof. Bäck discusses three mechanisms: TG lowering, anti-thrombotic effects, and resolution of inflammation.

What are potential mechanisms that may explain the benefits observed with icosapent ethyl? Prof. Bäck discusses three mechanisms: TG lowering, anti-thrombotic effects, and resolution of inflammation.

Recent clinical insights into icosapent ethyl

10' education - Oct. 3, 2022 - Prof. Deepak Bhatt, MD
It has been 3 years since the presentation and publication of the REDUCE-IT trial. What are more recent insights from subsequent analyses of the REDUCE-IT trial?

It has been 3 years since the presentation and publication of the REDUCE-IT trial. What are more recent insights from subsequent analyses of the REDUCE-IT trial?

Icosapent ethyl reduces MI overall and MI subtypes

News - Sep. 7, 2022

ESC 2022 An analysis of the REDUCE-IT trial showed that use of icosapent ethyl reduces the rate of MI overall, and of MI subtypes including STEMI, NSTEMI, MI leading to cardiac arrest and resuscitated MI, when compared to placebo.

Finding a place for fish oil in CVD prevention

10' education - Sep. 7, 2022 - Prof. Chris Packard, PhD
After presenting findings from the REDUCE-IT trial, prof. Packard discusses the place for icosapent ethyl. He talks about the need for a tailored approach in ASCVD patients with high risk.

After presenting findings from the REDUCE-IT trial, prof. Packard discusses the place for icosapent ethyl. He talks about the need for a tailored approach in ASCVD patients with high risk.

Final guidance by NICE in UK on recommendation for use of icosapent ethyl

News - July 19, 2022

NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.